Evidence map›Paper›PMID 33613730›Full record

ReviewAsian journal of pharmaceutical sciences2021

Trends of nanotechnology in type 2 diabetes mellitus treatment.

Yannis V Simos, Konstantinos Spyrou, Michaela Patila, Niki Karouta, Haralambos Stamatis, Dimitrios Gournis, Evangelia Dounousi, Dimitrios Peschos

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Amphiphilic, lauric acid-coupled pluronic-based nano-micellar system for efficient glipizide delivery.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yannis V SimosDepartment of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece.
Konstantinos SpyrouDepartment of Materials Science and Engineering, University of Ioannina, Ioannina 45110, Greece.
Michaela PatilaBiotechnology Laboratory, Department of Biological Applications and Technologies, University of Ioannina, Ioannina 45110, Greece.
Niki KaroutaDepartment of Materials Science and Engineering, University of Ioannina, Ioannina 45110, Greece.
Haralambos StamatisBiotechnology Laboratory, Department of Biological Applications and Technologies, University of Ioannina, Ioannina 45110, Greece.
Dimitrios GournisDepartment of Materials Science and Engineering, University of Ioannina, Ioannina 45110, Greece.
Evangelia DounousiDepartment of Nephrology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece.
Dimitrios PeschosDepartment of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece.
University of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are several therapeutic approaches in type 2 diabetes mellitus (T2DM). When diet and exercise fail to control hyperglycemia, patients are forced to start therapy with antidiabetic agents. However, these drugs present several drawbacks that can affect the course of treatment. The major disadvantages of current oral modalities for the treatment of T2DM are mainly depicted in the low bioavailability and the immediate release of the drug, generating the need for an increase in frequency of dosing. In conjugation with the manifestation of adverse side effects, patient compliance to therapy is reduced. Over the past few years nanotechnology has found fertile ground in the development of novel delivery modalities that can potentially enhance anti-diabetic regimes efficacy. All efforts have been targeted towards two main vital steps: (a) to protect the drug by encapsulating it into a nano-carrier system and (b) efficiently release the drug in a gradual as well as controllable manner. However, only a limited number of studies published in the literature used

Indexed as

Controlled releaseHyperglycemiaIn vivoNanotechnologyType 2 diabetes mellitus

Identifiers

PMID33613730
PMCPMC7878460
OpenAlexW3034111737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.